Alexion Pharmaceuticals

AstraZeneca Acquires Early-stage Gene Therapies from Pfizer

Alexion, AstraZeneca's rare disease division, has agreed to buy a portfolio of preclinical gene therapy programs and enabling technologies from competitor Pfizer for up to $1 billion, plus tiered royalties on sales.

AstraZeneca to Build API Plant in Ireland

AstraZeneca is building what it said is a “next-generation” active pharmaceutical ingredient (API) manufacturing plant for small molecules near Dublin, Ireland. A start-up date was not announced for the new facility that will be the Anglo-Swedish drugmaker’s first investment in the country.

Alexion Paying $8.4 Billion to Acquire Synageva

Roche's $8 billion InterMune Buy Not a Sign of More Big Deals

Alexion Recalls Certain Lots of Intravenous Drug Soliris

Roche Takes Its Hunt For A New Chairman Further Afield

Top-Selling Drugs for Ultra-Rare Diseases

Entering the Age of the $1 Million Medicine

Surge in Biotech Deals to Unlock Big Investor Profits